

Resource Summary Report

Generated by [NIF](#) on Aug 4, 2026

Chinese Glioma Genome Atlas

RRID:SCR_018802

Type: Tool

Proper Citation

Chinese Glioma Genome Atlas (RRID:SCR_018802)

Resource Information

URL: <http://www.cgga.org.cn/>

Proper Citation: Chinese Glioma Genome Atlas (RRID:SCR_018802)

Description: Web application for data storage and analysis to explore brain tumors datasets from Chinese cohorts. Data portal for storage and interactive exploration of multi-dimensional functional genomic data that includes primary and recurrent glioma samples from Chinese cohorts. Allows users to browse DNA mutation profile, mRNA/microRNA expression profile and methylation profile, and to do correlation and survival analysis in specific glioma subtype.

Abbreviations: CGGA

Resource Type: portal, disease-related portal, database, topical portal, data or information resource, data set

Defining Citation: [DOI:10.1101/2020.01.20.911982](https://doi.org/10.1101/2020.01.20.911982)

Keywords: Functional genomic data, glioma samples, brain tumor datasets, Chinese cohort, whole exome sequencing data, DNA methylation data, mRNA sequencing data, microRNA microarray data, clinical data, DNA mutation profile analysis, expression profile, methylation profile, survival analysis, glioma subtype, FASEB list

Related Condition: Glioma

Availability: Free, Freely available

Resource Name: Chinese Glioma Genome Atlas

Resource ID: SCR_018802

Record Creation Time: 20220129T080342+0000

Record Last Update: 20260804T043720+0000

Ratings and Alerts

No rating or validation information has been found for Chinese Glioma Genome Atlas.

No alerts have been found for Chinese Glioma Genome Atlas.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 877 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chiang YC, et al. (2026) Multi-Omics and Single-Cell Dissection of Exostosin Glycosyltransferases (EXT1/EXT2) Reveals Divergent Oncogenic Roles and Therapeutic Vulnerabilities in Gliomas. *Journal of Cancer*, 17(1), 177.

Tsai HC, et al. (2025) Acrolein induces exosomal miR-30a-5p/NCAM1 axis promoting glioma progression. *Molecular cancer therapeutics*.

Kundu S, et al. (2025) Inhibition of Extracellular Matrix Protein Fibulin-3 Reduces Immunosuppressive Signaling and Increases Macrophage Activation in Glioblastoma. *Cancer research communications*, 5(9), 1599.

Lv P, et al. (2025) Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma. *Scientific reports*, 15(1), 6314.

Li Y, et al. (2025) Multi-omics analysis identifies novels genes involved in glioma prognosis. *Scientific reports*, 15(1), 5806.

Chen C, et al. (2025) Developing and validating a prognostic disulfidptosis-related signature for glioblastoma: predicting radioresistance and synergistic effect with immunotherapy. *Journal of cancer research and clinical oncology*, 151(3), 112.

Liu Z, et al. (2025) Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets. *Biomarker research*, 13(1), 38.

Hui H, et al. (2025) Thioredoxin related transmembrane protein 1acts as a prognostic indictor and promotes proliferation and TMZ resistance of lower-grade glioma. *Scientific reports*, 15(1), 5246.

Xie S, et al. (2025) GOLPH3 inhibits glioma cell apoptosis through the JNK signaling pathway. *Frontiers in genetics*, 16, 1518573.

Shen L, et al. (2025) Analysis of ABCC3 in glioma progression: implications for prognosis, immunotherapy, and drug resistance. *Discover oncology*, 16(1), 179.

Qiu K, et al. (2025) LTF as a Potential Prognostic and Immunological Biomarker in Glioblastoma. *Biochemical genetics*, 63(3), 2347.

Cheng B, et al. (2025) EMB-driven glioblastoma multiforme progression via the MCT4/GPX3 axis: therapeutic inhibition by Ganxintriol A. *Journal of translational medicine*, 23(1), 272.

Zhao B, et al. (2025) A spatial transcriptomics study of MES-like and mono/macro cells in gliomas. *Scientific reports*, 15(1), 12730.

Zhang Y, et al. (2025) ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62-Mediated Selective Autophagy. *CNS neuroscience & therapeutics*, 31(1), e70168.

Liu J, et al. (2025) The AURKA inhibitor alters the immune microenvironment and enhances targeting B7-H3 immunotherapy in glioblastoma. *JCI insight*, 10(5).

Liao J, et al. (2025) Circadian rhythm related genes signature in glioma for drug resistance prediction: a comprehensive analysis integrating transcriptomics and machine learning. *Discover oncology*, 16(1), 119.

Wu Y, et al. (2025) A Risk Model Based on Ferroptosis-Related Genes OSMR, G0S2, IGFBP6, IGHG2, and FMOD Predicts Prognosis in Glioblastoma Multiforme. *CNS neuroscience & therapeutics*, 31(1), e70161.

Ding X, et al. (2025) Cisplatin and Alternating Temozolomide in Recurrent High-Grade Gliomas: Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase II Clinical Trial. *Clinical Medicine Insights. Oncology*, 19, 11795549251350188.

Liwei Z, et al. (2025) Robust prediction of glioma prognosis by hypoxia-induced ferroptosis genes: VEGFA-XBP1 co-expression for salvage therapy. *Cancer biology & therapy*, 26(1), 2529643.

Ao L, et al. (2025) Development, validation, and updating of prognostic models for m7G-associated genes from TAMs in lower-grade gliomas. *Scientific reports*, 15(1), 25146.